JPS6011422A - 抗筋ジストロフイ−症剤 - Google Patents

抗筋ジストロフイ−症剤

Info

Publication number: JPS6011422A
Authority: JP; Japan
Prior art keywords: antimyodystrophic; substance; agent; type; formula
Prior art date: 1983-06-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP58119427A

Other languages

English (en)

Japanese (ja)

Other versions

JPH0319208B2 (lt

Inventor

Hideyuki Yamato

英之大和

Noriyuki Toyoda

豊田　教之

Takami Fujii

藤井　孝美

Yuji Maeda

裕司前田

Tadaaki Kato

加藤　侃明

Chikao Yoshikumi

吉汲　親雄

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Kureha Corp

Original Assignee

Kureha Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-06-30

Filing date

1983-06-30

Publication date

1985-01-21

1983-06-30 Application filed by Kureha Corp filed Critical Kureha Corp

1983-06-30 Priority to JP58119427A priority Critical patent/JPS6011422A/ja

1984-06-15 Priority to US06/620,922 priority patent/US4501737A/en

1984-06-27 Priority to IT21627/84A priority patent/IT1176336B/it

1984-06-28 Priority to BE0/213228A priority patent/BE900026A/fr

1985-01-21 Publication of JPS6011422A publication Critical patent/JPS6011422A/ja

1991-03-14 Publication of JPH0319208B2 publication Critical patent/JPH0319208B2/ja

Status Granted legal-status Critical Current

Links

239000003795 chemical substances by application Substances 0.000 claims abstract description 8
FCKJYANJHNLEEP-XRWYNYHCSA-N (24R)-24,25-dihydroxycalciol Chemical group C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CC[C@@H](O)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C FCKJYANJHNLEEP-XRWYNYHCSA-N 0.000 claims abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
201000010099 disease Diseases 0.000 claims description 7
239000004480 active ingredient Substances 0.000 claims description 4
GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims description 4
239000004046 24R,25-dihydroxy-cholecalciferol Substances 0.000 claims 1
206010011732 Cyst Diseases 0.000 claims 1
208000031513 cyst Diseases 0.000 claims 1
239000000126 substance Substances 0.000 abstract description 21
230000000694 effects Effects 0.000 abstract description 7
FCKJYANJHNLEEP-SRLFHJKTSA-N 24,25-dihydroxycholecalciferol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCC(O)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C FCKJYANJHNLEEP-SRLFHJKTSA-N 0.000 abstract description 2
230000001162 anti-hypercalcemic effect Effects 0.000 abstract description 2
230000000259 anti-tumor effect Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
201000006938 muscular dystrophy Diseases 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
241001465754 Metazoa Species 0.000 description 6
210000003205 muscle Anatomy 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
235000014113 dietary fatty acids Nutrition 0.000 description 4
239000000194 fatty acid Substances 0.000 description 4
229930195729 fatty acid Natural products 0.000 description 4
150000004665 fatty acids Chemical class 0.000 description 4
150000002148 esters Chemical class 0.000 description 3
239000000203 mixture Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
230000007059 acute toxicity Effects 0.000 description 2
231100000403 acute toxicity Toxicity 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000003814 drug Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
239000007901 soft capsule Substances 0.000 description 2
235000010199 sorbic acid Nutrition 0.000 description 2
239000004334 sorbic acid Substances 0.000 description 2
229940075582 sorbic acid Drugs 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
208000035657 Abasia Diseases 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 1
241000257465 Echinoidea Species 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000007623 Lordosis Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000021642 Muscular disease Diseases 0.000 description 1
201000009623 Myopathy Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
208000005374 Poisoning Diseases 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
208000026928 Turner syndrome Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000767 anti-ulcer Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
238000010876 biochemical test Methods 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
230000001815 facial effect Effects 0.000 description 1
235000019688 fish Nutrition 0.000 description 1
230000008717 functional decline Effects 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
208000021005 inheritance pattern Diseases 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000001071 malnutrition Effects 0.000 description 1
235000000824 malnutrition Nutrition 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000003680 myocardial damage Effects 0.000 description 1
230000003274 myotonic effect Effects 0.000 description 1
208000015380 nutritional deficiency disease Diseases 0.000 description 1
235000014571 nuts Nutrition 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
231100000572 poisoning Toxicity 0.000 description 1
230000000607 poisoning effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
206010039722 scoliosis Diseases 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
238000003307 slaughter Methods 0.000 description 1
235000002639 sodium chloride Nutrition 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
239000010936 titanium Substances 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
-1 triglyceride ester Chemical class 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP58119427A 1983-06-30 1983-06-30 抗筋ジストロフイ−症剤 Granted JPS6011422A (ja)

Priority Applications (4)

Application Number	Priority Date	Filing Date	Title
JP58119427A JPS6011422A (ja)	1983-06-30	1983-06-30	抗筋ジストロフイ−症剤
US06/620,922 US4501737A (en)	1983-06-30	1984-06-15	Pharmaceutical composition containing 24,25-dihydroxycholecalciferol as an active ingredient to treat myodystrophia
IT21627/84A IT1176336B (it)	1983-06-30	1984-06-27	Composizione farmaceutica contenente come ingrediente attivo 24,25-diidrossicolecalciferolo
BE0/213228A BE900026A (fr)	1983-06-30	1984-06-28	Composition pharmaceutique contenant du 24,25-dihydroxy-cholecalciferol.

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP58119427A JPS6011422A (ja)	1983-06-30	1983-06-30	抗筋ジストロフイ−症剤

Publications (2)

Publication Number	Publication Date
JPS6011422A true JPS6011422A (ja)	1985-01-21
JPH0319208B2 JPH0319208B2 (lt)	1991-03-14

Family

ID=14761172

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP58119427A Granted JPS6011422A (ja)	1983-06-30	1983-06-30	抗筋ジストロフイ−症剤

Country Status (2)

Country	Link
US (1)	US4501737A (lt)
JP (1)	JPS6011422A (lt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1272953A (en) *	1984-10-08	1990-08-21	Yuji Makino	Pharmaceutical composition for external use containing active-type vitamin d.sub.3
US5001118A (en) *	1986-12-29	1991-03-19	Kureha Kagaku Kogyo Kabushiki Kaisha	Method for preventing senescence and increasing bone mass
US5350745A (en) *	1993-01-29	1994-09-27	Lunar Corporation	Treatment of myocardial failure

1983
- 1983-06-30 JP JP58119427A patent/JPS6011422A/ja active Granted
1984
- 1984-06-15 US US06/620,922 patent/US4501737A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JPH0319208B2 (lt)	1991-03-14
US4501737A (en)	1985-02-26

Publication	Publication Date	Title
NO328797B1 (no)	2010-05-18	Anvendelse av essensielle fettsyrer inneholdende en blanding av eikosapentaensyreetylester (EPA) og docosaheksaensyreetylester (DHA) for fremstilling av et medikament nyttig ved forebyggelse av dodsfall hos en pasient som har hatt et hjerteinfarkt.
JP2018516281A (ja)	2018-06-21	安定なカンナビノイド製剤
CN103732062A (zh)	2014-04-16	治疗多发性硬化以及保持和/或增加髓磷脂含量的方法
WO1995017889A1 (en)	1995-07-06	Therapeutic composition for hyperparathyroidism of patient subjected to artificial dialysis
JP3852621B2 (ja)	2006-12-06	血管内皮細胞機能改善剤
JPH0232015A (ja)	1990-02-01	薬剤の製造のためのモノ置換セレン有機化合物の使用、ならびにそれから製造される薬剤およびその薬剤の製造方法
JPS6011422A (ja)	1985-01-21	抗筋ジストロフイ−症剤
EP0149519B1 (en)	1990-06-27	Use of quinolones for the manufacture of a composition for the treatment of heart failure.
EP1345610B1 (en)	2006-12-06	Quetiapine for treating of dyskinesia in non-psychotic patients
JP2698865B2 (ja)	1998-01-19	筋緊張性ジストロフィー症治療剤
JPS60120812A (ja)	1985-06-28	糖尿病性骨減少症治療剤
WO2023192372A1 (en)	2023-10-05	Methods of treating sjögren-larssen syndrome
JP2008535907A5 (lt)	2009-05-21
KR20240036651A (ko)	2024-03-20	산화성 망막 질환의 진행을 억제하는 방법
JPH0319209B2 (lt)	1991-03-14
US10052305B2 (en)	2018-08-21	Lipoic acid and derivatives thereof for the treatment of cystinuria
JP7257091B2 (ja)	2023-04-13	認知症の治療及び予防薬
JP4896531B2 (ja)	2012-03-14	血中ＣｏＱ１０量を増加させる医薬組成物
JPS6221333B2 (lt)	1987-05-12
JPH02262519A (ja)	1990-10-25	糖尿病性神経障害治療剤
JPS6221330B2 (lt)	1987-05-12
CN118019529A (zh)	2024-05-10	抑制氧化性视网膜疾病进展的方法
US4701467A (en)	1987-10-20	Tolrestat as anti-hypertensive agent
JPS6011418A (ja)	1985-01-21	抗炎症剤
JP2026031529A (ja)	2026-02-24	認知機能障害の予防または治療に使用するための医薬組成物